RxDoctor Payments Data

Lauren Blair, NP

Family · Albany, NYNPI 1295397503

Payments from drug & device makers

$2,197in general payments, 2019–2025

Across 101 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$890
  • Urovant Sciences Inc$280
  • Antares Pharma, Inc.$191
  • Endo Pharmaceuticals Inc.$175
  • Sumitomo Pharma America, Inc.$154
  • AbbVie$124
  • plus $382 from 12 others

What the payments were for

  • Food & beverage$1,59272%
  • Education$60528%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,197 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$45,030
Medicare patients
205
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron151$152,580
GemtesaVibegron71$83,484
Mirabegron ErMirabegron16$7,295
Silodosin51$4,113
Tamsulosin Hcl228$3,205
Estradiol40$2,612
Dutasteride34$1,182
Finasteride87$974
Solifenacin Succinate13$723
Methenamine Hippurate16$686
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$442
NitrofurantoinNitrofurantoin Macrocrystal15$421
Alfuzosin Hcl ErAlfuzosin Hcl14$248
Cephalexin37$246
Ciprofloxacin Hcl17$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$890$152,580151 claims
Sumitomo Pharma America, Inc.Gemtesa$154$83,48471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →